Printer friendly

What does GCPJ stand for?

GCPJ stands for Good Clinical Practice Journal

This definition appears frequently and is found in the following Acronym Finder categories:

  • Organizations, NGOs, schools, universities, etc.

Other Resources:
We have 1 other meaning of GCPJ in our Acronym Attic

Samples in periodicals archive:

29 /PRNewswire-FirstCall/ -- PAREXEL International Corporation , a leading global biopharmaceutical services provider, in partnership with Glenmark Pharmaceuticals Ltd, today announced that it has been recognized by the Good Clinical Practice Journal (GCPj) as the winner of its Most Innovative Patient Recruitment Strategy Award.
LONDON, September 10 /PRNewswire/ -- GCPj Awards Clinical research professionals from all over the world gathered at the Gibson Hall in London Thursday 6 September for the inaugural Good Clinical Practice Journal (GCPj) Awards.
The Pharmaceutical/Biotechnology unit publishes the magazines Scrip, Good Clinical Practice Journal and BioPeople; newsletters Scrip World Pharmaceutical News, Scrip's Target World Drug Delivery News, BioVenture View, BioCommerce Abstracts and, Scrip Daily News Alert, an daily e-mail.
MILWAUKEE -- The Society for Clinical Data Management's (SCDM) Good Clinical Data Management Practices (GCDMP) document was awarded the Good Clinical Practice Journal (GCPj) Award for "Most Successful Company or Program of the Year in Raising GCP Standards" on September 6 in London.
A great deal of thought and planning has been put into these awards and it is our intention to honour and reward corporate and individual excellence and innovation throughout our industry," said Jenine Willis, Editor of the Good Clinical Practice Journal.
Report in Good Clinical Practice Journal (GCPj) Finds That Novartis Leads the Pack for Ongoing Trials in Autoimmune, Cardiovascular, and Metabolic Diseases Sanofi-aventis Takes the Top Rank for Ongoing Oncology Trials NEW YORK, June 30 /PRNewswire/ -- In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing clinical trials activity, and find that trial density is a particularly good indicator of the depth of companies' pipelines and focus of development efforts.